Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin therapy for opioid use disorder in early abstinence
ISRCTN10232579Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in opioid use disorder (OUD) (2 arms), sponsored by Imperial College London. Primary endpoint: Time to first opioid use. Started Nov 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ISRCTN10232579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10232579.